INTRAPERITONEAL PRODUCTION OF ERYTHROPOIETIN WITH CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS

被引：4

作者：

CHANDRA, M

CLEMONS, G

SAHDEV, I

MCVICAR, M

BLUESTONE, P

机构：

[1] Department of Pediatrics, North Shore University Hospital-Cornell University Medical College, Manhasset, 11030, NY

[2] Division of Biology and Medicine, Lawrence Berkeley Laboratories, University of California, Berkeley, California

[3] Department of Medicine, North Shore University Hospital-Cornell University Medical College, Manhasset, 11030, NY

来源：

PEDIATRIC NEPHROLOGY | 1993年 / 7卷 / 03期

关键词：

ERYTHROPOIETIN; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS;

D O I：

10.1007/BF00853222

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Higher hematocrit and serum erythropoietin (EPO) levels have previously been shown in end-stage renal disease patients treated with continuous ambulatory peritoneal dialysis (CAPD) compared with hemodialysis. We investigated whether EPO was produced intraperitoneally in CAPD patients. EPO concentration was 3.5 +/- 0.3 mU/ml by radioimmunoassay in 26 samples of peritoneal dialysis effluent obtained from 15 CAPD patients. EPO was not detectable in the fresh unused dialysate. No correlation was observed between EPO levels in the serum and dialysis effluent. Peritoneal macrophages were isolated from the dialysis effluent of 9 CAPD patients after an overnight dwell. The culture supernatant obtained after 24 h of in vitro culture of a million cells yielded EPO of 3.5 +/- 0.3 mU/ml. Our study demonstrated that peritoneal macrophages from CAPD patients produce EPO on in vitro stimulation, and EPO is present in the dialysis effluent of CAPD patients.

引用

页码：281 / 283

页数：3

共 20 条

[1]

Chandra M., Clemons G.K., McVicar M., Wilkes B., Bluestone P.A., Mailloux L.U., Mossey R.T., Serum erythropoietin levels and hematocrit in end-stage renal disease: influence of the mode of dialysis, Am J Kidney Dis, 12, pp. 208-213, (1988)

[2]

Zappacosta A.R., Caro J., Erslev A., Normalization of hematocrit in patients with end stage renal disease on continuous ambulatory peritoneal dialysis, Am J Med, 72, pp. 53-57, (1982)

[3]

Chandra M., McVicar M., Clemons G., Mossey R.T., Wilkes B.M., Role of erythropoietin in the reversal of anemia of renal failure with continuous ambulatory peritoneal dialysis: a case report, Nephron, 46, pp. 312-315, (1987)

[4]

Rich I.N., Kubanels B., Release of erythropoietin from macrophages mediated by phagocytosis of crystalline silica, J Reticuloendothelial Soc, 31, pp. 17-30, (1982)

[5]

Rich I.N., A role for the macrophage in normal haemopoiesis. II. Effect of varying physiological oxygen tensions on the release of haemopoietic growth factors from bone marrow derived macrophages in vitro, Exp Hematol, 14, pp. 746-751, (1986)

[6]

Garcia J.F., Ebbe S.N., Hollander L., Cutting H.O., Miller M.E., Cronkite E.P., Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings, J Lab Clin Med, 99, pp. 624-635, (1982)

[7]

Wideroe T.E., Sonengen T., Halvorsen S., Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis, Kidney Int, 24, pp. 208-218, (1983)

[8]

MacDougall I.C., Roberts D.E., Neubert P., Dharamasana A.D., Coles G.A., Willia J.D., Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis, Lancet, 1, pp. 425-427, (1989)

[9]

Kromer G., Solf A., Ehmer B., Kaufman B., Quellhorst E., Single dose pharmacokinetics of recombinant human erythropoietin comparing intravenous, subcutaneous and intraperitoneal administration in IPD patients, Kidney Int, 37, (1990)

[10]

Goldstein C.S., Bomalaski J.S., Zurier R.B., Neilsen E.G., Douglas S.D., Arlalysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis, Kidney Int, 26, (1984)

← 1 2 →